GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists can also help treat obesity. GLP-1 agonist medicines include injections and oral medications.
The global GLP-1 Agonist Injection market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for GLP-1 Agonist Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for GLP-1 Agonist Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of GLP-1 Agonist Injection include Novo Nordisk, Eli Lilly, AstraZeneca, GSK, Sanofi, Amylin, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for GLP-1 Agonist Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Agonist Injection.
The GLP-1 Agonist Injection market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global GLP-1 Agonist Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the GLP-1 Agonist Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Novo Nordisk
Eli Lilly
AstraZeneca
GSK
Sanofi
Amylin
Huadong Medicine
Shanghai Benemae Pharmaceutical Corporation
Segment by Type
Short-acting Preparations
Long-acting Preparations
Segment by Application
Diabetes
Obesity
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of GLP-1 Agonist Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of GLP-1 Agonist Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 GLP-1 Agonist Injection Market Overview
1.1 Product Definition
1.2 GLP-1 Agonist Injection by Type
1.2.1 Global GLP-1 Agonist Injection Market Value Comparison by Type (2024-2030)
1.2.2 Short-acting Preparations
1.2.3 Long-acting Preparations
1.3 GLP-1 Agonist Injection by Application
1.3.1 Global GLP-1 Agonist Injection Market Value by Application (2024-2030)
1.3.2 Diabetes
1.3.3 Obesity
1.4 Global GLP-1 Agonist Injection Market Size Estimates and Forecasts
1.4.1 Global GLP-1 Agonist Injection Revenue 2019-2030
1.4.2 Global GLP-1 Agonist Injection Sales 2019-2030
1.4.3 Global GLP-1 Agonist Injection Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 GLP-1 Agonist Injection Market Competition by Manufacturers
2.1 Global GLP-1 Agonist Injection Sales Market Share by Manufacturers (2019-2024)
2.2 Global GLP-1 Agonist Injection Revenue Market Share by Manufacturers (2019-2024)
2.3 Global GLP-1 Agonist Injection Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of GLP-1 Agonist Injection, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of GLP-1 Agonist Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of GLP-1 Agonist Injection, Product Type & Application
2.7 Global Key Manufacturers of GLP-1 Agonist Injection, Date of Enter into This Industry
2.8 Global GLP-1 Agonist Injection Market Competitive Situation and Trends
2.8.1 Global GLP-1 Agonist Injection Market Concentration Rate
2.8.2 The Global 5 and 10 Largest GLP-1 Agonist Injection Players Market Share by Revenue
2.8.3 Global GLP-1 Agonist Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global GLP-1 Agonist Injection Market Scenario by Region
3.1 Global GLP-1 Agonist Injection Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global GLP-1 Agonist Injection Sales by Region: 2019-2030
3.2.1 Global GLP-1 Agonist Injection Sales by Region: 2019-2024
3.2.2 Global GLP-1 Agonist Injection Sales by Region: 2025-2030
3.3 Global GLP-1 Agonist Injection Revenue by Region: 2019-2030
3.3.1 Global GLP-1 Agonist Injection Revenue by Region: 2019-2024
3.3.2 Global GLP-1 Agonist Injection Revenue by Region: 2025-2030
3.4 North America GLP-1 Agonist Injection Market Facts & Figures by Country
3.4.1 North America GLP-1 Agonist Injection Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America GLP-1 Agonist Injection Sales by Country (2019-2030)
3.4.3 North America GLP-1 Agonist Injection Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe GLP-1 Agonist Injection Market Facts & Figures by Country
3.5.1 Europe GLP-1 Agonist Injection Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe GLP-1 Agonist Injection Sales by Country (2019-2030)
3.5.3 Europe GLP-1 Agonist Injection Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific GLP-1 Agonist Injection Market Facts & Figures by Region
3.6.1 Asia Pacific GLP-1 Agonist Injection Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific GLP-1 Agonist Injection Sales by Region (2019-2030)
3.6.3 Asia Pacific GLP-1 Agonist Injection Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America GLP-1 Agonist Injection Market Facts & Figures by Country
3.7.1 Latin America GLP-1 Agonist Injection Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America GLP-1 Agonist Injection Sales by Country (2019-2030)
3.7.3 Latin America GLP-1 Agonist Injection Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa GLP-1 Agonist Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa GLP-1 Agonist Injection Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa GLP-1 Agonist Injection Sales by Country (2019-2030)
3.8.3 Middle East and Africa GLP-1 Agonist Injection Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global GLP-1 Agonist Injection Sales by Type (2019-2030)
4.1.1 Global GLP-1 Agonist Injection Sales by Type (2019-2024)
4.1.2 Global GLP-1 Agonist Injection Sales by Type (2025-2030)
4.1.3 Global GLP-1 Agonist Injection Sales Market Share by Type (2019-2030)
4.2 Global GLP-1 Agonist Injection Revenue by Type (2019-2030)
4.2.1 Global GLP-1 Agonist Injection Revenue by Type (2019-2024)
4.2.2 Global GLP-1 Agonist Injection Revenue by Type (2025-2030)
4.2.3 Global GLP-1 Agonist Injection Revenue Market Share by Type (2019-2030)
4.3 Global GLP-1 Agonist Injection Price by Type (2019-2030)
5 Segment by Application
5.1 Global GLP-1 Agonist Injection Sales by Application (2019-2030)
5.1.1 Global GLP-1 Agonist Injection Sales by Application (2019-2024)
5.1.2 Global GLP-1 Agonist Injection Sales by Application (2025-2030)
5.1.3 Global GLP-1 Agonist Injection Sales Market Share by Application (2019-2030)
5.2 Global GLP-1 Agonist Injection Revenue by Application (2019-2030)
5.2.1 Global GLP-1 Agonist Injection Revenue by Application (2019-2024)
5.2.2 Global GLP-1 Agonist Injection Revenue by Application (2025-2030)
5.2.3 Global GLP-1 Agonist Injection Revenue Market Share by Application (2019-2030)
5.3 Global GLP-1 Agonist Injection Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novo Nordisk GLP-1 Agonist Injection Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Company Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eli Lilly GLP-1 Agonist Injection Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Company Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AstraZeneca GLP-1 Agonist Injection Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 GSK
6.4.1 GSK Company Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GSK GLP-1 Agonist Injection Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Company Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sanofi GLP-1 Agonist Injection Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Amylin
6.6.1 Amylin Company Information
6.6.2 Amylin Description and Business Overview
6.6.3 Amylin GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Amylin GLP-1 Agonist Injection Product Portfolio
6.6.5 Amylin Recent Developments/Updates
6.7 Huadong Medicine
6.7.1 Huadong Medicine Company Information
6.7.2 Huadong Medicine Description and Business Overview
6.7.3 Huadong Medicine GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Huadong Medicine GLP-1 Agonist Injection Product Portfolio
6.7.5 Huadong Medicine Recent Developments/Updates
6.8 Shanghai Benemae Pharmaceutical Corporation
6.8.1 Shanghai Benemae Pharmaceutical Corporation Company Information
6.8.2 Shanghai Benemae Pharmaceutical Corporation Description and Business Overview
6.8.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonist Injection Product Portfolio
6.8.5 Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 GLP-1 Agonist Injection Industry Chain Analysis
7.2 GLP-1 Agonist Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 GLP-1 Agonist Injection Production Mode & Process
7.4 GLP-1 Agonist Injection Sales and Marketing
7.4.1 GLP-1 Agonist Injection Sales Channels
7.4.2 GLP-1 Agonist Injection Distributors
7.5 GLP-1 Agonist Injection Customers
8 GLP-1 Agonist Injection Market Dynamics
8.1 GLP-1 Agonist Injection Industry Trends
8.2 GLP-1 Agonist Injection Market Drivers
8.3 GLP-1 Agonist Injection Market Challenges
8.4 GLP-1 Agonist Injection Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Novo Nordisk
Eli Lilly
AstraZeneca
GSK
Sanofi
Amylin
Huadong Medicine
Shanghai Benemae Pharmaceutical Corporation
*If Applicable.